arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Vivos Therapeutics, Inc.

VVOS

$0.15 ▼ -0.01 (-4.66%) at close

8 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Moderately Bearish

auto_awesome

Analytical Summary

Vivos Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.5M

Dividend Yield —

Revenue Growth 16.0% ↗

Op. Margin -114.1% ↘

ROIC 2132.5% ↗

FCF / Share $-1.71 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.51

info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$17.44M

↑ +16.0% —

Net Income Profit after all expenses

$-21.17M

↓ -90.1% —

Operating Margin Operating profit as % of sales

-114.1%

↓ -53.5% 2th

FCF / Share Free cash flow per share

$-1.71

↑ +35.1% —

Long-Term Debt Long-term obligations

$753.00K

↓ -41.6% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	16.0% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+101%)	8.9% Fair ↑ Fair Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+11%)	-13.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-273%)	-5.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-164%)	29.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+265%)	14.7% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+84%)	—	—
EPS Growth YoY (%)	6.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	80.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-971.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-8.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-90.1% Weak ↓ Weak Declining Year-over-year change in net income	18.0% Good ↑ Good Improving Year-over-year change in net income	43.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-17.5% Weak ↑ Weak Improving Year-over-year change in net income	-68.3% Weak Weak Year-over-year change in net income	-12.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	35.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	74.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1172922.9% Weak Weak Year-over-year change in free cash flow	-4.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	2.9% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	-3.8% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	1.8% Weak Weak Compound annual revenue growth over 3 years	12.0% Good Good Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	5.9% Fair Fair Compound annual revenue growth over 5 years	5.7% Fair Fair Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-114.1% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-860%)	-74.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-595%)	-125.3% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-935%)	-156.2% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1141%)	-120.7% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-905%)	-92.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-714%)	-92.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-719%)	—
Profit Margin (%) (%)	-121.4% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1111%)	-74.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-717%)	-98.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-920%)	-148.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1340%)	-120.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1101%)	-92.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-869%)	-94.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-887%)	—
FCF Margin (%) (%)	-100.9% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-88.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-92.4% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-128.0% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-107.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-44.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-48.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.51x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	2132.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-111.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3324.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-411.9% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-63.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-52.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-1090.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-79.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-73.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-161.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-182.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-60.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-140.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-140.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1033%)	—	—	-79.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-630%)	-71.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-575%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	-0.51x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-184%)	—	—	—	—	0.08x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-87%)	-1.26x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-310%)	—
Interest Coverage (x)	-14.21x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1241.22x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-12515.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1455.86x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-125.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	-76.72x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-1.28M	$-6.26M	$-1.64M	$-3.52M	$-24.03M	$-16.92M	$3.24M	—
Debt / EBITDA (x)	-0.04x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	-0.11x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.36x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$1.70	$2.99	$11.32	$0.00	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-2.07	$-2.22	$-11.14	$-1.04	$-0.96	—	—	—
Free Cash Flow per Share (USD)	$-1.71	$-2.64	$-10.46	$-0.00	$-0.00	—	—	—
Book Value per Share (USD)	$-0.16	$1.35	$0.22	$0.21	$1.11	$0.93	$-0.24	—
Tangible Book Value per Share (USD)	$-1.52	$0.80	$-1.56	$0.07	$0.97	$0.77	$-0.51	—
Basic Weighted Avg Shares (shares)	10.27M	5.02M	1.22M	23.01B	21.23B	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$-13.69M	$2.50M	$-4.83M	$-1.39M	$19.82M	$12.55M	$-7.11M	—
LT Debt (USD)	$753.00K	—	—	—	—	$1.29M	$3.71M	—
Total Equity (USD)	$-1.49M	$7.95M	$411.00K	$4.80M	$25.54M	$16.92M	$-2.94M	$4.83M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$17.44M	$15.03M	$13.80M	$16.02M	$16.89M	$13.07M	$11.39M	—
Depreciation Expense (USD)	$1.31M	$581.00K	$621.00K	$669.00K	$733.00K	$300.00K	$326.85K	—
Net Income, GAAP (USD)	$-21.17M	$-11.14M	$-13.58M	$-23.84M	$-20.29M	$-12.06M	$-10.75M	—
Operating Cash Flow (USD)	$-15.26M	$-12.69M	$-11.95M	$-19.59M	$-15.73M	$-5.68M	$-5.34M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters

Vivos Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VVOS with peers